240 related articles for article (PubMed ID: 24850846)
1. Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients.
Litvinov IV; Cordeiro B; Huang Y; Zargham H; Pehr K; Doré MA; Gilbert M; Zhou Y; Kupper TS; Sasseville D
Clin Cancer Res; 2014 Jul; 20(14):3799-808. PubMed ID: 24850846
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
3. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
[TBL] [Abstract][Full Text] [Related]
4. Serological detection of cutaneous T-cell lymphoma-associated antigens.
Eichmuller S; Usener D; Dummer R; Stein A; Thiel D; Schadendorf D
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):629-34. PubMed ID: 11149944
[TBL] [Abstract][Full Text] [Related]
5. Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma.
Litvinov IV; Netchiporouk E; Cordeiro B; Zargham H; Pehr K; Gilbert M; Zhou Y; Moreau L; Woetmann A; Ødum N; Kupper TS; Sasseville D
Oncoimmunology; 2014 Nov; 3(11):e970025. PubMed ID: 25941598
[TBL] [Abstract][Full Text] [Related]
6. Identification of selectively expressed genes and antigens in CTCL.
Hartmann TB; Mattern E; Wiedemann N; van Doorn R; Willemze R; Niikura T; Hildenbrand R; Schadendorf D; Eichmüller SB
Exp Dermatol; 2008 Apr; 17(4):324-34. PubMed ID: 17979976
[TBL] [Abstract][Full Text] [Related]
7. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
[TBL] [Abstract][Full Text] [Related]
8. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.
Nihal M; Ahmad N; Wood GS
Cell Cycle; 2014; 13(4):632-40. PubMed ID: 24343700
[TBL] [Abstract][Full Text] [Related]
9. The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL).
Gantchev J; Martínez Villarreal A; Xie P; Lefrançois P; Gunn S; Netchiporouk E; Sasseville D; Litvinov IV
Front Oncol; 2019; 9():429. PubMed ID: 31214493
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity.
Eichmüller S; Usener D; Thiel D; Schadendorf D
Int J Cancer; 2003 Apr; 104(4):482-7. PubMed ID: 12584747
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
13. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
14. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
15. BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.
Esmailzadeh S; Huang Y; Su MW; Zhou Y; Jiang X
Leukemia; 2015 Jun; 29(6):1402-13. PubMed ID: 25578476
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
17. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract][Full Text] [Related]
18. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
19. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.
Nieto-Rementería N; Pérez-Yarza G; Boyano MD; Apraiz A; Izu R; Díaz-Pérez JL; Asumendi A
Br J Dermatol; 2009 Mar; 160(3):519-26. PubMed ID: 19067706
[TBL] [Abstract][Full Text] [Related]
20. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]